Tarsus Pharmaceuticals, Inc.
TARS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001819790
In the last 90 days, Tarsus Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 6 sales; 256 institutions reported holding it in 13F filings for Q2 2026, worth $2.98B in total; no superinvestor holds it.
Q2 2021 vs. Q1 2021
How the institutions holding Tarsus Pharmaceuticals, Inc. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 41 | 44 | +3 |
| Shares | 12.8M | 13.1M | +299.8K (+2.3%) |
| Value | $410.4M | $378.5M | −$31.8M (−7.8%) |
New holders (10)
Institutions that held Tarsus Pharmaceuticals, Inc. at the end of Q2 2021 but not at the end of Q1 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Cowen and Company, LLC | 514,289 | $14.9M | 0.79% |
| Jefferies Group LLC | 442,993 | $12.8M | 0.22% |
| Ghost Tree Capital, LLC | 170,000 | $4.93M | 1.54% |
| Altium Capital Management LP | 70,573 | $2.04M | 0.47% |
| J. Goldman & Co LP | 33,751 | $978.0K | 0.06% |
| SG Americas Securities, LLC | 22,977 | $666.0K | 0.00% |
| Pura Vida Investments, LLC | 16,686 | $484.0K | 0.03% |
| Morgan Stanley | 8,282 | $241.0K | 0.00% |
| Virtus ETF Advisers LLC | 6,319 | $183.0K | 0.08% |
| Signaturefd, LLC | 27 | $1.00K | 0.00% |
Sold out (7)
Institutions that held Tarsus Pharmaceuticals, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| Millennium Management LLC | 84,854 | $2.73M |
| HighVista Strategies LLC | 21,084 | $680.0K |
| Endurant Capital Management LP | 14,143 | $456.0K |
| Woodline Partners LP | 12,310 | $397.0K |
| UBS Group AG | 2,496 | $80.0K |
| Wells Fargo & Company | 1,941 | $63.0K |
| Bank of Montreal | 192 | $5.00K |